Irisin vs Adiponectin
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and Adiponectin (Adiponectin (Acrp30, AdipoQ)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Irisin | Adiponectin |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Adiponectin (Acrp30, AdipoQ) |
| Molecular Weight | ~12.3 kDa | ~26.4 kDa (monomer) |
| Half-Life | hours | ~2-4 h |
| Amino Acids | 112 | 244 |
| Typical Dose | No approved human dose; research use only | No approved human dose; research use only |
| Route | IV|SC | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 86 |
| Research Status | Pre-clinical | Pre-clinical |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
Irisin Dosing
not established|not established
Adiponectin Dosing
not established|not established
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.